Shopping Cart 0
Cart Subtotal
USD 0

ARCA biopharma Inc (ABIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

ARCA Biopharma Inc (ARCA), formerly Nuvelo Inc is a developer of genetically targeted therapies for cardiovascular diseases. The company's product candidate include Gencaro, a mild vasodilator and investigational pharmacologically unique beta-blocker that is being developed for the treatment and prevention of atrial fibrillation in patients with heart failure and reduced left ventricular ejection fraction. It provides medical treatment to the individual genetic characteristics of each patient and personalized medicine approach to drug development. ARCA also develops AB171, a thiol-substituted isosorbide mononitrate for genetically targeted treatment of peripheral arterial disease and heart failure. The company works in partnership with universities to improve the health of cardiovascular patients. ARCA is headquartered in Westminster, Colorado, the US.

ARCA biopharma Inc (ABIO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ARCA biopharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

ARCA biopharma Inc, Medical Devices Deals, 2012 to YTD 2018 10

ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Arca Biopharma Extends Co-Development Agreement with Medtronic for Gencaro 12

Equity Offering 13

ARCA biopharma Raises USD0.1 Million in Public Offering of Shares 13

Arca Biopharma Raises USD37 Million in Private Placement of Units 14

ARCA biopharma Files Registration Statement For Public Offering Of Securities For USD 75 Million 16

Arca Biopharma Completes Public Offering Of Shares For USD 8.7 Million 17

Arca Biopharma Completes Public Offering Of Preferred Shares For USD 20 Million 18

Arca Biopharma Completes Private Placement Of Securities For USD 1.25 Million 19

ARCA biopharma Completes Public Offering Of Shares For USD 0.7 Million 20

Arca Biopharma Completes Private Placement Of Units For USD 0.25 Million 21

ARCA biopharma Completes Private Placement Of Units For USD 0.325 Million 22

ARCA biopharma Completes Public Offering Of Units For USD 1 Million 23

ARCA biopharma Inc-Key Competitors 25

ARCA biopharma Inc-Key Employees 26

ARCA biopharma Inc-Locations And Subsidiaries 27

Head Office 27

Recent Developments 28

Financial Announcements 28

May 08, 2018: ARCA Biopharma announces first quarter 2018 financial results and provides corporate update 28

Mar 22, 2018: ARCA biopharma Announces Fiscal Year 2017 Financial Results and Provides Corporate Update 29

Nov 09, 2017: ARCA biopharma Announces Third Quarter 2017 Financial Results and Provides Business Update 30

Aug 03, 2017: ARCA biopharma Announces Second Quarter 2017 Financial Results and Provides Business Update 31

May 15, 2017: ARCA Biopharma Announces First Quarter 2017 Financial Results 33

May 15, 2017: ARCA Biopharma Q1 net loss increases 34

Mar 21, 2017: ARCA biopharma Announces Fiscal Year 2016 Financial Results and Provides Business Update 35

Corporate Communications 37

Feb 21, 2017: Anders Hove, MD Joins ARCA biopharma Board of Directors 37

Product News 38

03/06/2017: ARCA biopharma Announces 175th Patient Randomized into the GENETIC-AF Phase 2B/3 Clinical Trial 38

01/18/2017: ARCA biopharma Announces 150th Patient Randomized into the GENETIC-AF Phase 2B/3 Clinical Trial 39

Clinical Trials 40

Feb 26, 2018: ARCA biopharma Reports Topline Phase 2B Results for GENETIC-AF Clinical Trial 40

Jan 08, 2018: ARCA biopharma Announces Completion of GENETIC-AF Phase IIB Clinical Trial 42

Aug 16, 2017: ARCA biopharma Announces Completion of Enrollment for GENETIC-AF Phase 2B Clinical Trial 43

Aug 09, 2017: ARCA biopharma Announces GENETIC-AF Data and Safety Monitoring Board Recommendation to Complete Phase 2B GENETIC-AF Clinical Trial Based on Efficacy and Safety Data in Phase 2B Interim Analysis 44

Jun 20, 2017: ARCA Biopharma Announces Database Lock for GENETIC-AF Phase 2B Interim Efficacy Analysis-DSMB Recommendation Anticipated in August 2017 45

May 15, 2017: ARCA Biopharma Provides Update on Gencaro 46

Appendix 47

Methodology 47

About GlobalData 47

Contact Us 47

Disclaimer 47


List Of Figure

List of Figures

ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

ARCA biopharma Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

ARCA biopharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ARCA biopharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ARCA biopharma Inc, Deals By Therapy Area, 2012 to YTD 2018 9

ARCA biopharma Inc, Medical Devices Deals, 2012 to YTD 2018 10

ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Arca Biopharma Extends Co-Development Agreement with Medtronic for Gencaro 12

ARCA biopharma Raises USD0.1 Million in Public Offering of Shares 13

Arca Biopharma Raises USD37 Million in Private Placement of Units 14

ARCA biopharma Files Registration Statement For Public Offering Of Securities For USD 75 Million 16

Arca Biopharma Completes Public Offering Of Shares For USD 8.7 Million 17

Arca Biopharma Completes Public Offering Of Preferred Shares For USD 20 Million 18

Arca Biopharma Completes Private Placement Of Securities For USD 1.25 Million 19

ARCA biopharma Completes Public Offering Of Shares For USD 0.7 Million 20

Arca Biopharma Completes Private Placement Of Units For USD 0.25 Million 21

ARCA biopharma Completes Private Placement Of Units For USD 0.325 Million 22

ARCA biopharma Completes Public Offering Of Units For USD 1 Million 23

ARCA biopharma Inc, Key Competitors 25

ARCA biopharma Inc, Key Employees 26

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

ARCA biopharma Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

ARCA Biopharma Inc (ARCA), formerly Nuvelo Inc is a developer of genetically targeted therapies for cardiovascular diseases. The company's product candidate include Gencaro, a mild vasodilator and investigational pharmacologically unique beta-blocker that is being developed for the treatment and prevention of atrial fibrillation in patients with heart failure and reduced left ventricular ejection fraction. It provides medical treatment to the individual genetic characteristics of each patient and personalized medicine approach to drug development. ARCA also develops AB171, a thiol-substituted isosorbide mononitrate for genetically targeted treatment of peripheral arterial disease and heart failure. The company works in partnership with universities to improve the health of cardiovascular patients. ARCA is headquartered in Westminster, Colorado, the US.

ARCA biopharma Inc (ABIO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ARCA biopharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

ARCA biopharma Inc, Medical Devices Deals, 2012 to YTD 2018 10

ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Arca Biopharma Extends Co-Development Agreement with Medtronic for Gencaro 12

Equity Offering 13

ARCA biopharma Raises USD0.1 Million in Public Offering of Shares 13

Arca Biopharma Raises USD37 Million in Private Placement of Units 14

ARCA biopharma Files Registration Statement For Public Offering Of Securities For USD 75 Million 16

Arca Biopharma Completes Public Offering Of Shares For USD 8.7 Million 17

Arca Biopharma Completes Public Offering Of Preferred Shares For USD 20 Million 18

Arca Biopharma Completes Private Placement Of Securities For USD 1.25 Million 19

ARCA biopharma Completes Public Offering Of Shares For USD 0.7 Million 20

Arca Biopharma Completes Private Placement Of Units For USD 0.25 Million 21

ARCA biopharma Completes Private Placement Of Units For USD 0.325 Million 22

ARCA biopharma Completes Public Offering Of Units For USD 1 Million 23

ARCA biopharma Inc-Key Competitors 25

ARCA biopharma Inc-Key Employees 26

ARCA biopharma Inc-Locations And Subsidiaries 27

Head Office 27

Recent Developments 28

Financial Announcements 28

May 08, 2018: ARCA Biopharma announces first quarter 2018 financial results and provides corporate update 28

Mar 22, 2018: ARCA biopharma Announces Fiscal Year 2017 Financial Results and Provides Corporate Update 29

Nov 09, 2017: ARCA biopharma Announces Third Quarter 2017 Financial Results and Provides Business Update 30

Aug 03, 2017: ARCA biopharma Announces Second Quarter 2017 Financial Results and Provides Business Update 31

May 15, 2017: ARCA Biopharma Announces First Quarter 2017 Financial Results 33

May 15, 2017: ARCA Biopharma Q1 net loss increases 34

Mar 21, 2017: ARCA biopharma Announces Fiscal Year 2016 Financial Results and Provides Business Update 35

Corporate Communications 37

Feb 21, 2017: Anders Hove, MD Joins ARCA biopharma Board of Directors 37

Product News 38

03/06/2017: ARCA biopharma Announces 175th Patient Randomized into the GENETIC-AF Phase 2B/3 Clinical Trial 38

01/18/2017: ARCA biopharma Announces 150th Patient Randomized into the GENETIC-AF Phase 2B/3 Clinical Trial 39

Clinical Trials 40

Feb 26, 2018: ARCA biopharma Reports Topline Phase 2B Results for GENETIC-AF Clinical Trial 40

Jan 08, 2018: ARCA biopharma Announces Completion of GENETIC-AF Phase IIB Clinical Trial 42

Aug 16, 2017: ARCA biopharma Announces Completion of Enrollment for GENETIC-AF Phase 2B Clinical Trial 43

Aug 09, 2017: ARCA biopharma Announces GENETIC-AF Data and Safety Monitoring Board Recommendation to Complete Phase 2B GENETIC-AF Clinical Trial Based on Efficacy and Safety Data in Phase 2B Interim Analysis 44

Jun 20, 2017: ARCA Biopharma Announces Database Lock for GENETIC-AF Phase 2B Interim Efficacy Analysis-DSMB Recommendation Anticipated in August 2017 45

May 15, 2017: ARCA Biopharma Provides Update on Gencaro 46

Appendix 47

Methodology 47

About GlobalData 47

Contact Us 47

Disclaimer 47


List Of Figure

List of Figures

ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

ARCA biopharma Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

ARCA biopharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ARCA biopharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ARCA biopharma Inc, Deals By Therapy Area, 2012 to YTD 2018 9

ARCA biopharma Inc, Medical Devices Deals, 2012 to YTD 2018 10

ARCA biopharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Arca Biopharma Extends Co-Development Agreement with Medtronic for Gencaro 12

ARCA biopharma Raises USD0.1 Million in Public Offering of Shares 13

Arca Biopharma Raises USD37 Million in Private Placement of Units 14

ARCA biopharma Files Registration Statement For Public Offering Of Securities For USD 75 Million 16

Arca Biopharma Completes Public Offering Of Shares For USD 8.7 Million 17

Arca Biopharma Completes Public Offering Of Preferred Shares For USD 20 Million 18

Arca Biopharma Completes Private Placement Of Securities For USD 1.25 Million 19

ARCA biopharma Completes Public Offering Of Shares For USD 0.7 Million 20

Arca Biopharma Completes Private Placement Of Units For USD 0.25 Million 21

ARCA biopharma Completes Private Placement Of Units For USD 0.325 Million 22

ARCA biopharma Completes Public Offering Of Units For USD 1 Million 23

ARCA biopharma Inc, Key Competitors 25

ARCA biopharma Inc, Key Employees 26

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

ARCA biopharma Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.